000 01599 a2200433 4500
005 20250515065947.0
264 0 _c20071213
008 200712s 0 0 eng d
022 _a1551-4005
024 7 _a10.4161/cc.6.10.4182
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aBonuccelli, Gloria
245 0 0 _aLocalized treatment with a novel FDA-approved proteasome inhibitor blocks the degradation of dystrophin and dystrophin-associated proteins in mdx mice.
_h[electronic resource]
260 _bCell cycle (Georgetown, Tex.)
_cMay 2007
300 _a1242-8 p.
_bdigital
500 _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aBoronic Acids
_xpharmacology
650 0 4 _aBortezomib
650 0 4 _aDipeptides
_xpharmacology
650 0 4 _aDystrophin
_xmetabolism
650 0 4 _aDystrophin-Associated Proteins
_xmetabolism
650 0 4 _aMale
650 0 4 _aMice
650 0 4 _aMice, Inbred mdx
650 0 4 _aMicroscopy, Fluorescence
650 0 4 _aMuscle, Skeletal
_xmetabolism
650 0 4 _aMuscular Dystrophy, Duchenne
_xdrug therapy
650 0 4 _aNF-kappa B
_xmetabolism
650 0 4 _aProtease Inhibitors
_xpharmacology
650 0 4 _aPyrazines
_xpharmacology
700 1 _aSotgia, Federica
700 1 _aCapozza, Franco
700 1 _aGazzerro, Elisabetta
700 1 _aMinetti, Carlo
700 1 _aLisanti, Michael P
773 0 _tCell cycle (Georgetown, Tex.)
_gvol. 6
_gno. 10
_gp. 1242-8
856 4 0 _uhttps://doi.org/10.4161/cc.6.10.4182
_zAvailable from publisher's website
999 _c17040797
_d17040797